Oral Lesion as Unusual First Manifestation of Multiple Myeloma: Case Reports and Review of the Literature

Table 2

Number of patients	Regimen description	Response rate	Notes	Reference
275; 54 w EMP	Bortezomib based + ASCT	Not reported	Retrospective series; EMP is an independent factor for PFS and OS only in transplant-ineligible patients	Lee et al. [19]
1	(1) VTD + ASCT; (2) Bortezomib + tanespimycin	Not reported	Case report	Kumar et al. [20]
97 (plasmacytoma evolved to MM)	Radiotherapy versus novel agents/chemotherapy	91.8%	Retrospective series; Immunoparesis was the only negative predictor of progression to MM	Katodritou et al. [21]
36; (EMP with invasion of the spinal cord)	Bortezomib based	13/36 (including complete remission)		Zhang and Zhong [22]
50; (intracranial MM)	Bortezomib based ()	18/29 (CR + VGPR)	Retrospective series	Gozzetti et al. [23]